We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » New Ruling Revives Lawsuit Against Sanofi for “Low Dosing” Fabry Disease Drug
New Ruling Revives Lawsuit Against Sanofi for “Low Dosing” Fabry Disease Drug
Judges from the U.S. Court of Appeals for the First Circuit have revived a nearly 12-year-old lawsuit that charged Sanofi with damaging the health of patients with a rare liver disease by selling virally contaminated Fabrazyme (agalsidase beta) the only medication approved for the condition — and then rationing it at drastically reduced doses.